zerlasiran

Zerlasiran is a short interfering RNA (siRNA) gene-silencing therapy in development for the treatment of patients with elevated lipoprotein(a) [Lp(a)], a genetically determined cardiovascular risk factor. It works by targeting and silencing the LPA gene, which encodes the protein component of Lp(a). By inhibiting this gene, zerlasiran significantly reduces circulating Lp(a) levels—by more than 80% on average in clinical trials—with effects persisting for up to 60 weeks after dosing. Elevated Lp(a) is associated with increased risk of atherosclerotic cardiovascular disease (ASCVD), heart attacks, and strokes. Zerlasiran is being developed by Silence Therapeutics and has completed Phase 2 trials demonstrating efficacy and safety; further Phase 3 studies are planned[1][4][5][6][7].